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Our goal is to define the properties of cell-imperme-
able cargo molecules that can be delivered into cells
by pH (Low) Insertion Peptide (pHLIP), which can
selectively target tumors invivobasedon their acidity.
Using biophysical methods and fluorescence micros-
copy, we show that pHLIP can successfully deliver
polar and membrane-impermeable cyclic peptides
linked to its C terminus through the membranes of
lipid vesicles and cancer cells. Our results also indi-
cate that the translocation of these cargo molecules
is pH dependent and mediated by transmembrane
helix formation. Since a broad range of cell-imperme-
able molecules is excluded from discovery efforts
because they cannot traverse membranes on their
own, we believe that pHLIP has the potential to
expand therapeutic options for acidic tissues such
as tumors and sites of inflammation.
INTRODUCTION
Since many anticancer drugs have off-target side effects that
severely limit the efficacy of chemotherapy (Fennelly, 1995;
Ross and Small, 2002; Sehouli et al., 2002), the use of targeted
drug delivery systems has emerged as a way to diminish such
cytotoxic effects on healthy organs (Minko et al., 2004). Some,
such as liposomes (Fenske and Cullis, 2005), polymers (Duncan,
2006; Haag and Kratz, 2006), and other nanoparticles (Torchilin,
2007; Yezhelyev et al., 2006), can passively target tumors due
to the enhanced permeation and retention effect from the
increased permeability and minimal lymphatic drainage of
many solid tumors (Maeda et al., 2001; Maeda et al., 2000).
However, this effect is small for certain tumors, including those
that are preangiogenic, necrotic, or poorly vascularized (Allen
and Cullis, 2004). Therefore, other specific targeting strategies
have been developed, usually involving the addition of ligands
that target a particular type of binding site on cancer cells.
Most cancer cells overexpress certain receptors and enzymes
(cancer biomarkers) due to the change in biology required for
tumor progression (Hanrahan et al., 2005). For example, the
receptors for luteinizing hormone-releasing hormone are overex-
pressed in breast, ovarian, and prostate cancer cells (Dharap
and Minko, 2003; Dharap et al., 2003; Minko et al., 2004). Unfor-
tunately, an important limitation of targeting specific binding
sites is the heterogeneity of human tumors. Tumor cells are754 Chemistry & Biology 16, 754–762, July 31, 2009 ª2009 Elseviergenetically and phenotypically complex, due in part to the accu-
mulation of a large number of somatic mutations in the cancer
genome and to the genetic variations in individual patients, so
that only a subset of the cells in a tumor may be targeted and
the rest continue to proliferate (Bild et al., 2006a, 2006b; Murphy
et al., 2005). Cancer cells inside the same tumor or in different
tumors from the same origin might then have different receptors
on their surface. Thus, it may not be enough to rely on a single
cancer biomarker even for one type of cancer or a single tumor,
so it is important to ask which other features of tumors may be
exploited for targeting.
Rapidly expanding cancer cells have abnormal nutritional
requirements and metabolic traits, creating unique microenvi-
ronmental features that distinguish almost all malignant solid
tumors from surrounding normal tissues. One such character-
istic is the lower extracellular pH of tumors when compared
with healthy tissues (pH 6.5–7.0 versus pH 7.2–7.4) (Cairns
et al., 2006; Gerweck and Seetharaman, 1996). Acidosis results
in part from the specially evolved metabolism of cancer cells, of
which the most notable is theWarburg effect (i.e., the preference
to use glycolysis to generate ATP, even in the presence of
oxygen) (Kim and Dang, 2006), which leads to the accumulation
of lactic acid in the cytoplasm and subsequent excretion of
protons out of the cell. Other factors also contribute to extracel-
lular acidity, such as the release of carbon dioxide from cancer
cells (Helmlinger et al., 2002), poor clearance of extracellular
protons by intratumor microvessels (Gatenby and Gillies,
2004), and induction of carbonic anhydrase IX in solid tumor
tissues (Gatenby and Gillies, 2004; Swietach et al., 2007). For
these reasons, acidosis is a hallmark of tumor progression
from early to advanced stages and may provide an opportunity
for tumor detection and targeted therapy (Junior et al., 2007;
Mrkvan et al., 2005; Sethuraman et al., 2006).
Many pharmaceutical agentsmust reach specific organelles in
the interior of the cell to exert their therapeutic action, e.g.,
agents of gene therapy need to reach the nucleus and proapop-
totic anticancer drugs need access to mitochondria (Torchilin,
2008). However, the hydrophobic barrier of cell membranes
prevents drug carriers from entering cells unless an active trans-
port mechanism is involved. In a number of cases, the strategy is
to rely on the endocytotic pathways to internalize the drug carrier
and its payload. Various cell-penetrating proteins or peptides
have shown the ability to deliver therapeutic agents into cells,
with their cargo payload ranging from small molecules, peptides,
and proteins to RNA and DNA polymers (Fischer et al., 2005; Fu-
taki, 2006; Henriques et al., 2006; Martin and Rice, 2007; Wag-
staff and Jans, 2006). Many of the these peptides contain fewer
than 20 amino acids and are highly enriched in Arg or Lys, suchLtd All rights reserved
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(Elmquist et al., 2001), and other artificially designed peptides
(Futaki et al., 2001). However, when taken up by some form of
endocytosis, peptide drug conjugates and other delivery nano-
particles are still topologically outside of the cell, with endosomal
membranes separating the cargomolecules from the cytoplasm.
Thus, additional devices, such as GALA peptides or the
N-terminal domain of the influenza virus hemagglutinin protein
HA2 (Li et al., 2004; Stegmann, 2000), are used to facilitate the
endosomal escape. These efforts highlight the need for delivery
systems that directly transport drug molecules into the cell
cytoplasm.
As an alternative, our method is based on pH (Low) Insertion
Peptide (pHLIP), a peptide that inserts into lipid bilayers at acidic
pH. Unlike other strategies, which may consist of a carrier
component, a targeting agent, andan endosomal escapemoiety,
the pHLIP peptide can simultaneously target tumors, carry the
cargo, and translocate thepayload across theplasmamembrane
at low pH. pHLIP is a 36 amino acid peptide derived from the
C helix of bacteriorhodopsin (Hunt et al., 1997). At pH above 7,
pHLIP peptides are soluble as monomers in aqueous buffers
and associate with lipid bilayer surfaces largely as unstructured
peptides. Under acidic conditions, pHLIP inserts across a lipid
bilayerwith anapparent pKof 6 in vitro, forminga transmembrane
helix (Hunt et al., 1997). The mechanism and thermodynamics of
pHLIP-membrane interaction have been studied extensively
(Hunt et al., 1997; Reshetnyak et al., 2008; Tang and Gai, 2008;
Zoonens et al., 2008). At peptide concentrations below 7 mM,
pHLIP is predominantly monomeric in all three states—in solu-
tion, on the membrane, and in the membrane (Reshetnyak
et al., 2007). The pH-dependent insertion process is coupled to
the protonation of one or both of the Asp residues located in
the transmembrane region of the peptide (Hunt et al., 1997; Re-
shetnyak et al., 2006). Furthermore, pHLIP insertion seems to
be reversible and unidirectional, with its C terminus translocated
across the membrane (Reshetnyak et al., 2006, 2007). Once in-
serted, pHLIP helices causeminimal disturbance to phospholipid
bilayers: they do not form pores or induce membrane permeabi-
lization (Reshetnyak et al., 2006; Zoonens et al., 2008).
We have shown that pHLIP can accumulate and persist in vivo
in tissues with mildly acidic environments (pH 6.5–7.0), including
solid tumors inmice and inflammatory foci in rats. In comparison,
pHLIP accumulation is much less favorable in healthy tissues,
with their extracellular milieu at a physiological pH of 7.2–7.4.
In a mouse breast adenocarcinoma model, fluorescently labeled
pHLIP constructs found solid acidic tumors with a high degree
of accuracy and accumulated in them, even at very early stages
of tumor development (Andreev et al., 2007). In addition, pHLIP
shows no toxicity to cells (Reshetnyak et al., 2006) or mice
(Andreev et al., 2007) at concentrations tested (1–50 mM).
The insertion of pHLIP into lipid bilayers, leading to the forma-
tion of stable transmembrane helices, is associated with an
energy release. We have established that this energy can be
used to move cargo molecules across a membrane, raising the
possibility of targeted drug delivery (Reshetnyak et al., 2006). It
is also worth noting that pHLIP-mediated translocation of cargo
molecules into cells is not mediated by endocytosis, interactions
with cell surface receptors, or formation of pores in cell
membranes (Reshetnyak et al., 2006).Chemistry & Biology 16However, there has not been any systematic exploration of the
properties of cargomolecules that can be delivered. To this point
we have only a scattering of data on themolecular characteristics
that define what constitutes useable cargo molecules. Indeed,
the properties of the cargos that have been previously shown to
be translocated by pHLIP into the cytoplasm of cells were not
well known or carefully controlled (Reshetnyak et al., 2006). For
instance, when we described the phalloidin cargo as ‘‘cell imper-
meable’’ we neglected the presence of the Rhodamine (TRITC)
moiety (octanol/water partition coefficient [Log Po/w] = +2.9;
molecular weight [MW] = 516) and the photocrosslinker (Log
Po/w = +0.8; MW = 212, used to attached phalloidin-TRITC to
pHLIP), resulting in a cargo molecule much less polar than the
phalloidin alone, which has a Log Po/w of2.9 (MW = 788). Simi-
larly, the dansyl dye cargo has a calculated Log Po/w of +3,
making it potentially cell permeable on its own.
The goal of the present study is to define the useful range of
chemical properties for cargo molecules deliverable by pHLIP-
mediated translocation. To accomplish this objective, we take
advantage of the fact that a wide range of properties, such as
polarity, charge, size, and shape, can be varied systematically
in a host-guest model cyclic peptide. We show that pHLIP can
successfully translocate cell-impermeable, polar cyclic peptides
(Log Po/w = 3; MW 800) through the membranes of lipid vesi-
cles and cancer cells. Hence, we suggest that pHLIP can deliver
membrane-impermeable molecules that are usually excluded
from being tested as potential therapeutic agents, expanding
the range of molecular alternatives.
RESULTS AND DISCUSSION
Design of Cargo Molecules
We chose cyclic hexapeptides as model cargo molecules in this
study, to avoid ambiguities that might arise from alternative
conformations that linear peptides might adopt in the various
environments found in solution, at a membrane surface, or in a
membrane interior. The cargo structures are shown in Figure 1A.
These 7-nitrobenz-2-oxa-1,3-diazole (NBD)-cyclic-(X)4 peptides
(NC(X)4) contain four X positions that are varied as Ser, Asp, Asn,
or Arg residues, allowing adjustments of cargo polarity, as shown
by their Log Po/w calculated using QikProp (Table 1). Overall,
these cargo molecules were designed to be quite hydrophilic
(Log Po/w < 2.5), with the objective of making them membrane
impermeable on their own. To follow the cargo and test for
topology, we included a Lys residue carrying the NBD fluores-
cenceprobe, and to serveas thepoint of attachment to thecarrier
pHLIP peptide via a S-S disulfide bond we have an SH group.
The Designed Cargo Molecules are Membrane
Impermeable
We used the dithionite (S2O4
-2) quenching of NBD fluorescence
to confirm that the NC(X)4 cargo peptides behave in accordance
with our design and cannot cross a lipid bilayer on their own at
the pH used to activate pHLIP translocation. For each cargo,
NBD fluorescence was monitored at 530 nm (excited at 480 nm)
when incubated with 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC) vesicles at pH 4.0. Figure 1B shows that
addition of the membrane-impermeable dithionite ion leads to
rapid, complete quenching of NBD fluorescence of all four, 754–762, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 755
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NBD is conjugated to the C terminus of pHLIP in the control
construct pHLIP-NBD (100% protection). These results indicate
that the C terminus of pHLIP is located inside the vesicles at
pH 4, thus protecting NBD from dithionite quenching, while the
NC(X)4 cyclic cargo peptides stay outside. Slow quenching of
NBD fluorescence is sometimes observed on a time scale of
minutes, as can be seen for the pHLIP-NBD conjugate, perhaps
due to leakage of dithionite or its decomposition products (Lem
andWayman, 1970; Wayman and Lem, 1970) into the liposomes
at pH 4. As mentioned in the Experimental Procedures section,
protection is evaluated from the first data point collected
immediately after addition of dithionite (denoted by a circle in
Figure 1B).
We also tested howNC(X)4 peptides would behave in the pres-
ence of human cancer cells in an acidic environment by moni-
toring NBD fluorescence via confocal microscopy. Figure 1C
shows that these cargo peptides do not cross the membrane
of HeLa cells when incubated at pH 6.2. Indeed, with the excep-
tion of a few dead cells, no fluorescence is observed in the cyto-
plasm of the cells. Thus, these cargo molecules cannot cross a
lipid bilayer or a cell membrane on their own.
Interactions of pHLIP-Cargo Constructs
with Lipid Bilayers
Prior to evaluating pHLIP-mediated translocation of cyclic
peptides into lipid vesicles and cancer cells, each NC(X)4 cargo
peptide was conjugated to the C terminus region of pHLIP-Cys
via a disulfide bond. The interactions of these pHLIP-cargo
constructs with lipid bilayers were then studied using circular
dichroism (CD) and tryptophan fluorescence.
Figure 1. Cargo Peptides Do Not Cross Lipid
Membrane on their Own
(A) Structures of the NC(X)4 cargo peptides. The four
peptides studied in this work, NC(Ser)4, NC(Asp)4,
NC(Asn)4, and NC(Arg)4, follow the same model: four vari-
able positions (X), a Cys residue for conjugation to pHLIP,
and a NBD fluorescent probe attached to the side chain of
a Lys residue.
(B) Dithionite quenching of NBD fluorescence signals of
the NC(X)4 cargo peptides (2 mM) not attached to pHLIP
and of both N-terminal NBD-pHLIP and C-terminal
pHLIP-NBD constructs (2 mM) in the presence of lipo-
somes (peptide/lipid = 1:400) at pH 4.0. The arrows indi-
cate the time of addition of dithionite. The circle indicates
the first data point collected after the addition of dithionite.
(C) NBD fluorescence images of NC(X)4 cargo peptides
(5 mM) incubated with HeLa cells at pH 6.2 (top) and the
corresponding phase-contrast images (bottom).
Far UV CD spectroscopy was used to deter-
mine the secondary structure of various pHLIP
constructs in the presence of POPC liposomes
at pH 8 and 4 (Figures 2A and 2B). Figure 2A
shows that every pHLIP conjugate adopts an
unstructured configuration at pH 8, whereas
Figure 2B shows that all pHLIP conjugates
form a helices under acidic conditions similar
to that formed by pHLIP at pH 4, except for
pHLIP-NC(Arg)4. The latter remains unstructured when the pH
is lowered from 8 to 4.
There are two Trp residues present in the sequence of pHLIP,
and at least one of them is in the postulated transbilayer region
of the peptide. Thus, since the Trp fluorescence emission is
sensitive to the polarity of the environment, they serve as reporter
groups for monitoring the interactions of pHLIP (or pHLIP con-
jugates) with lipid bilayers in POPC vesicles. At pH 8, the Trp
fluorescence emission maxima of all pHLIP conjugates (except
pHLIP-NC(Arg)4) are centered around350nm (Figure 2C), reflect-
ing the exposure of Trp residues to polar, aqueous environments
(Burstein et al., 1973). Lowering thepH from8 to4 results in signif-
icant lmax blue shifts (R10 nm, except for pHLIP-NC(Arg)4) and
increases in fluorescence intensity (except for pHLIP-NC(Asn)4).
These changes are characteristic for Trp residues buried in
hydrophobic environments and suggest that at least pHLIP-
NC(Asp)4 and pHLIP-NC(Ser)4 conjugates insert into vesicles at
pH 4 (Burstein et al., 1973; Reshetnyak et al., 2007).
These findings agree with the pH-responsive changes in
secondary structure revealed by CD. Taken together, notwith-
standing the NC(Arg)4 exception, these results indicate that
conjugating a NC(X)4 cargo peptide (or an NBD reporter group)
to pHLIP does not disturb its characteristic shape-shifting
behavior. Moreover, in very recent tryptophan fluorescence
experiments, we measured the pK of insertion of pHLIP-
NC(Asp)4 into the bilayer of POPC vesicles to be 5.9 ± 0.1
(data not shown), which is very close to the value of 6.0
measured for pHLIP alone (Hunt et al., 1997). In other words,
acidic environments can induce pHLIP conjugates to insert
into lipid bilayers to form stable transmembrane a helices in a
fashion similar to that of pHLIP.756 Chemistry & Biology 16, 754–762, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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other pHLIP conjugates: its Trp lmax is already centered around
340 nm at pH 8 (Figure 2C), reflecting sequestration of Trp resi-
dues away from water—a state possibly mediated by aggrega-
tion. Furthermore, the Trp lmax does not change significantly
when the pH is lowered, which is consistent with the unstruc-
tured CD spectra observed at both pH 8 and 4 for this conjugate.
In short, the pHLIP-NC(Arg)4 construct seems to aggregate.
pHLIP-Mediated Translocation
We assessed the ability of pHLIP to translocate NC(X)4 cargos
across lipid bilayers and cell membranes. The conjugates were
first tested with lipid vesicles. Figure 3A shows that when
pHLIP-NC(X)4 conjugates are incubated at pH 8 with POPC vesi-
cles, addition of dithionite quenches NBD fluorescence in a rapid
and complete fashion (0% protection) for all four pHLIP-NC(X)4
conjugates, i.e., cargo molecules stay outside of the liposomes
and are not translocated across lipid bilayers at neutral pH.
However, when the pH is lowered to 4, different NBD fluores-
cence quenching traces are observed among the conjugates
(Figure 3B). For pHLIP-NC(Asn)4 and pHLIP-NC(Arg)4 conju-
gates, NBD fluorescence is completely quenched by dithionite
even at pH 4, with 0.4 ± 1.8% and 3 ± 5% protection observed,
respectively (see Table 2), suggesting that these two conjugates
leave their cargos outside of the liposomes under acidic condi-
tions. In contrast, near complete protection from dithionite
quenching is observed for pHLIP-NBD (91 ± 9%, positive
control), pHLIP-NC(Asp)4 (85 ± 7%), and pHLIP-NC(Ser)4 (76 ±
8%) conjugates, showing that these three C-terminal cargos,
with Log Po/w values in the range of 0.8 to 2.9, are success-
fully translocated into or across lipid bilayers by pHLIP. The
quantitative results for these translocation assays are summa-
rized in Table 2. As already shown in Figure 1B for pHLIP-NBD,
slow quenching of NBD after addition of dithionite is also
observed for pHLIP-NC(Ser)4 and pHLIP-NC(Asp)4, indicating
that this effect is not specific to the (Ser)4 and (Asp)4 cargos
and that these two cargos do not cause membrane distortion re-
sulting in major liposome leakage.
We also evaluated the capability of pHLIP to deliver NC(X)4
cargos across membranes and into the cytoplasm of HeLa cells
usingNBD fluorescencemicroscopy. The results are in complete
agreement with that observed in liposomes. Figures 3C and 4
show that NC(Asp)4 and NC(Ser)4 cargos are translocated and
released into cell cytoplasms (since the S-S bond that conju-
gates the cargo to pHLIP is cleaved in cells) only when the cells
are incubated at pH 6.2. In contrast, pHLIP-NC(Asn)4 and pHLIP-
Table 1. Properties of Cargo Molecules Attached to the
C Terminus of pHLIP
C-Terminal
Cargo
Log Po/w
(Deprotonated)a
Log Po/w
(Protonated)a MWa
NBD 0.83 0.83 293.3
NC(Ser)4 2.68 2.68 742.7
NC(Asp)4 11.92 2.87 854.8
NC(Asn)4 8.52 8.52 850.8
NC(Arg)4 4.34 4.34 1025.2
a Log Po/w were calculated using QikProp 3.0 from the structures with
deprotonated or protonated side chain carboxyl groups.Chemistry & Biology 16NC(Arg)4 do not deliver their cargos into cell cytoplasms, regard-
less of the pH. In the case of pHLIP-NC(Arg)4, the conjugate
seems to stick to cell plasma membranes and aggregate on
the glass window at both pHs, further confirming what we
observed by CD (Figures 2A and 2B) and Trp fluorescence
(Figure 2C). This behavior is perhaps caused by interactions
between the multiple positive charges on the cargo peptide
NC(Arg)4 and the multiple negative charges on pHLIP (which
has six carboxyl side chains) at neutral pH. In the case of
pHLIP-NC(Asn)4, we suggest that it is the polarity of the cargo
(Log Po/w 8.5) that prevents pHLIP constructs from inserting
across lipid bilayers (at an appreciable rate), since its CD and
Trp fluorescence data are consistent with the notion that this
pHLIP conjugate undergoes a clear transition from random coil
to helix when pH is decreased from 8 to 4. Furthermore, the
pHLIP-NC(Asn)4 construct seems to stick to the surface of
HeLa cells at pH 6.2 as revealed by fluorescence microscopy
(Figure 3C). Perhaps, this conjugate aggregates at or binds to
the membrane surface as an a helix, as CD data suggest (Fig-
ure 2B). It is also interesting that even though NC(Asp)4 is more
hydrophilic than NC(Asn)4 at neutral pH (calculated Log Po/w of
11.9 versus8.5; see Table 1), the aspartic acid cargo is trans-
located into cells at pH 6.2 while the asparagine cargo is not, in
agreement with what is observed in liposome quenching assays
carried out at pH 4. Such behavior can be explained by the fact
that the carboxylate side chains of NC(Asp)4 can be protonated
(by cell surface protons), leading to a significant decrease in
cargo polarity (from a calculated Log Po/w of nearly 12 to
2.9), making the crossing of the hydrophobic bilayer interior
less formidable. The local environment at the cell surface (i.e.,
the phospholipid head group region) could significantly increase
the pKa of the carboxylate side chains of the Asp residue from its
canonical values of3.9, making the protonationmore favorable
at pH 6.2.
Moreover, even though NC(Ser)4 and NC(Asp)4 share similar
Log Po/w values (about 3), they differ slightly in their molecular
weights (742.7 versus 854.8, respectively), yet pHLIP translo-
cates them with the same efficiency (76 ± 8% versus 85 ± 7%,
respectively). This suggests that a Log Po/w of 3 (and MW of
850) may not represent absolute set limits and that pHLIP
may be able to translocate even more polar or larger molecules.
Remarkably, the results obtained with the lipid vesicles corre-
late very well with that found in the presence of cancer cells. This
finding supports the idea that liposomes are appropriate models
to study pHLIP-mediated translocations in cells and that pHLIP
peptides traverse cell membranes via direct insertion into the
bilayer, reinforcing the view that pHLIP-assisted translocation
is not mediated by membrane proteins or endocytosis.
SIGNIFICANCE
In conventional drug design aimed at intracellular targets,
a constraint has been to create molecules that are suffi-
ciently hydrophobic and/or small to traverse membranes on
their own (Log Po/w from 0.4 to +5.6 and molecular weight
[MW] of 160 to 480 g.mol1). As a result, cell-impermeable
and larger molecules are usually excluded. Furthermore,
many cancer drugs have off-target side effects that severely
limit the efficacy of chemotherapy. In this work, we have, 754–762, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 757
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system by defining some of the properties of molecules that
can be translocated into cells; thus establishing boundary
conditions for a new arena of drug design using this
approach. Our method is based on pHLIP, a 36 amino acid
peptide that is soluble at physiological pH and binds to
membrane lipid bilayer surfaces if they are present. Unlike
other strategies, it can simultaneously target tumors, carry
the cargo, insert as a transmembrane helix, and translocate
the payload across the plasmamembrane at low pH.We find
Figure 2. Interactions of pHLIP-Cargo
Constructs with Lipid Bilayers
(A and B) CD spectra of pHLIP-cargo variants
(7 mM) in the presence of POPC vesicles at
pH 8.0 (A) and pH 4.0 (B).
(C) Tryptophan fluorescence spectra of pHLIP-
cargo variants (2 mM) mixed in the presence of
POPC vesicles at pH 8.0 (red spectra) and at
pH 4.0 (blue spectra). The corresponding maxima
of fluorescence emission are indicated by dotted
lines.
that cargomoleculeswith a LogPo/w of
3 and MW of 800 are efficiently
delivered into cancer cells. As a
comparison, there is, to the best of
our knowledge, no example of an exist-
inganticancerdrugwithaLogPo/w<1
and MW >500 that has intracellular
targets. Thus, pHLIP may help to
expand the chemical space for anti-
cancer (and anti-inflammatory) drugs
to include polar, cell-impermeable
molecules aimed at cytoplasmic
targets. Because such drug molecules
will not easily cross cell membranes in
normal tissues, certain side effects
associated with conventional chemo-
therapy may also be mitigated.
EXPERIMENTAL PROCEDURES
Peptide Design and Synthesis
Two variants of pHLIP were used in this study:
pHLIP-Cyswith a cysteine residue at itsC terminus
and Cys-pHLIP with a cysteine at its N terminus.
They have the following sequences: pHLIP-Cys,
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADE
GTCG; Cys-pHLIP, ACEQNPIYWARYADWLFTT
PLLLLDLALLVDADEGTG. Both variants were
prepared by solid-phase peptide synthesis and
purified via reverse-phase HPLC at the W.M.
Keck Foundation Biotechnology Resource Labo-
ratory (Yale University).
The cargo molecules are synthetic cyclic
peptides following a host-guest model, called
NBD-Cyclic-(X)4 or NC(X)4, where X is Arg, Asn,
Asp, or Ser (Figure 1A). These cyclic hexapepti-
des also contain a Lys where the fluorescence
probe NBD is attached and a Cys residue to allow
conjugation to pHLIP via a disulfide bond. These
cyclic peptides were purchased from Anaspec, Inc. and subsequently conju-
gated to pHLIP-Cys using methods described below. The Log Po/w of these
cyclic cargo peptides was calculated using QikProp 3.0 (Schro¨dinger, LLC)
for Windows (W. Jorgensen, Yale University) from the structures with depro-
tonated or protonated side chain carboxyl groups.
Syntheses of pHLIP Conjugates
Synthesis of pHLIP-S-S-NC(Ser)4
Solvent mixture A consists of 1:1:3:5 of DMF, DMSO, methanol, and aqueous
NH4HCO3 buffer (200 mM; pH 8). To a solution of TCEP.HCl (0.765 mg,
2.67 mmol, 3.38 eq.) in 85 ml of solvent mixture A was added a solution of758 Chemistry & Biology 16, 754–762, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows indicate the time of addition of the quencher sodium dithionite. The circles indicate the first data point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by confocal
microscopy.cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mmol, 1 eq.) in 340 ml of A, followed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in the dark for 20 min. To this
reduced mixture, an oxidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous NH4HCO3 buffer (200 mM; pH 8) was added.
This reaction mixture was stirred at room temperature for 5 hr, and then
allowed to sit at 0C for 16 hr. The desired product was isolated via
Table 2. Percentage of Protection from Dithionite Quenching of
NBD Fluorescence via pHLIP Insertion-Mediated Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Cargo
Percentage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% 0.83 293.3 U
NC(Ser)4 76 ± 8% 2.68 742.7 U
NC(Asp)4 85 ± 7% 2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% 8.52 850.8 X
NC(Arg)4 3 ± 5% 4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully protonated cyclic peptide
structures.Chemistry & Biology 1reverse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in 50% yield. The product was quantified using UV-vis absorbance of the
NBD group (3 280 nm 2,080 M1cm1, 3 348 nm 9,800 M1cm1, 3 480
nm 26,000 M1cm1) and pHLIP peptide (3 280 nm 13,940 M1cm1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often using a simplified, milder procedure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, the reaction proceeded as a heteroge-
neous mixture (perhaps due to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Syntheses of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous potassium phosphate buffer (100 mM; pH 7.25)6, 754–762, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 759
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trobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine [Invitrogen]; 0.3 mg, 0.7 mmol,
1 eq.) in 300 ml of DMF. This reaction mixture was stirred at room temperature
in the dark under argon for 20 hr. The desired adducts were isolated in >85%
yield via C18 HPLC using methods described previously. The products were
quantified using the 498 nm absorbance of the secondary amine NBD
group (3 498 nm 23,500 M1cm1). MS (MALDI-TOF MS+): molecular weight
calculated for pHLIP-NBD (C208H306N50O62S): 4531.0. Found (MH
+): 4531.4.
Molecular weight calculated for NBD-pHLIP (C205H301N49O61S): 4459.9. Found
(MH+): 4460.6.
Liposome Preparation
Ten milligrams of POPC (Avanti Polar Lipids) in chloroform were dried under
a stream of argon and then held under vacuum overnight. The dried lipid film
was rehydrated with 1 ml of 100 mM sodium phosphate and 50 mM NaCl
(buffer B) (pH 8.0) and vortexed. The resulting multilamellar vesicles were
freeze-thawed in liquid nitrogen for seven cycles and were extruded through
a polycarbonate membrane with 100 mm diameter pores using a mini extruder
(Avanti Polar Lipids) to obtain unilamellar vesicles. Liposomes were used
immediately following their preparation. Lipid concentration was checked
using Marshall’s assay (Stewart, 1980).
Sample Preparation for CD and Fluorescence Measurements
Prior to CD or fluorescence measurements, stock solutions of pHLIP
constructs (0.2–0.5mM) were prepared in acetonitrile/water (1:1). The concen-
tration of the stock solution was determined byUV-vis absorption in 6M guani-
dine-HCl (3280 = 13,940 M
1 cm1; 3480 = 25,000 M
1 cm1). This stock solu-
tion was diluted to the working pHLIP concentration (of 2 or 7 mM)with buffer B
and incubated overnight at room temperature in the dark. On the next day,
when appropriate, solutions of POPC liposomes (prepared in buffer B) were
Figure 4. Representative Example of pHLIP-Assisted Translocation
and Release of Cargo Molecules into the Cytoplasm of HeLa Cells
Confocal fluorescence microscopy images of pHLIP-NC(Asp)4 (5 mM) incu-
bated in the presence of HeLa cells at pH 6.2. Single projection of a z stack
of 15 confocal sections (A), yz cross-section (red axis) (B), and xz cross-section
(blue axis) (C).760 Chemistry & Biology 16, 754–762, July 31, 2009 ª2009 Elsevieadded to the diluted pHLIP solution at a 1:400 peptide-to-lipid molar ratio
and incubated for 3 hr at room temperature in the dark at pH 8.0. Subse-
quently, attempts at pHLIP insertion into the liposome lipid bilayer were trig-
gered by reducing the pH from 8.0 to 4.0 with the addition of aliquots of a
HCl solution. This mixture was allowed to equilibrate at pH 4 for 30 min prior
to fluorescence and CD measurements.
Fluorescence Spectroscopy: Trp Fluorescence Measurements
and NBD Fluorescence Quenching Assays
Measurements were carried out using a SLM-Aminco 8000C spectrofluorim-
eter (ISS) equipped with a thermo-bath RTE-111 (Neslab). All measurements
were performed at 25C and with pHLIP peptide concentrations equal to
2 mM. To minimize light scattering effects, the emission polarizer was oriented
at 0 and the excitation polarizer at 90. The widths of the emission and exci-
tation slits were set to 4 nm. When tryptophan emission was monitored (pHLIP
has two Trp residues), the samples were excited at 295 nm and the emission
spectra were taken from 300 to 500 nm. When monitoring NBD fluorescence,
the samples were excited at 480 nm and the fluorescence signal was moni-
tored at 530 nm in slow kinetic mode.
pHLIP-mediated cargo translocation into liposomes was determined using
the NBD-dithionite quenching reaction: membrane-impermeable dithionite
ion (S2O4
2) can chemically modify the NBD fluorophore and quench its fluo-
rescence (McIntyre and Sleight, 1991). Changes in the fluorescence signal of
NBD were monitored upon addition of 5 ml of sodium dithionite (Na2S2O4) (pH
4.0; 1 M sodium phosphate; final dithionite concentration in the cuvette =
0.5–2 mM) to a 95 ml sample of pHLIP construct in buffer B that had been incu-
bated in the presence of liposomes at pH 4.0 for 30 min. Fresh dithionite stock
solution was prepared for eachmeasurement because dithionite decomposes
rapidly at low pH (Lem and Wayman, 1970; Wayman and Lem, 1970). The
percentages of protection are calculated from the first data point collected after
addition of dithionite.
CD Spectroscopy
Far UV CD spectra of pHLIP constructs were recorded on an Aviv model 215
spectrometer equipped with a Peltier thermal-controlled cuvette holder. All
measurements were performed at 25C and with pHLIP constructs prepared
as mentioned above and at concentrations equal to 7 mM. CD intensities are
expressed in mean residue molar ellipticity [q] calculated from the following
equation:
½q= qobs
10:l:c:n

in degrees cm2:dmol1

;
where qobs is the observed ellipticity in millidegrees, l is the optical path length
in centimeters, c is the final molar concentration of the peptide, and n is the
number of amino acid residues. Samples were measured in a 0.1 cm path
length quartz cuvette and raw data were acquired from 260 nm to 190 nm at
1 nm intervals using a 2 s averaging time, and at least two scanswere averaged
for each sample.
Cancer Cell Assay and Confocal Fluorescence Microscopy
HeLa cells (kind gift from Dr. Mooseker, Yale University) were grown in 35-mm
dishes with a 12-mm glass-bottom window (WillCo Wells) in DMEM supple-
mented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin in a
humidified atmosphere of 5% CO2 at 37
C. After 48 hr of culture, cells were
washed twice with PBS buffer at the desired experimental pH and then incu-
bated for 1 hr in PBS buffer at pH 7.4 or 6.2 in the presence of NC(X)4 or
pHLIP-S-S-NC(X)4 (5 mM). After incubation, the cells were washed with PBS
buffer at the experimental pH and fresh DMEM was then added. Fluorescent
images were taken by using a Zeiss LSM 510 confocal microscope equipped
with a 203 Plan-Apochromat (NA 0.8) objective and with excitation at 488 nm.
A series of optical planes (z stack) were acquired using a 633 oil objective.
Images were acquired by Zeiss ZEN software and processed using ImageJ
(Abramoff et al., 2004) and the OrtView plug-in (MedNuc).
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